

# House Research Act Summary

**CHAPTER:** 289

**SESSION:** 2010 Regular Session

**TOPIC:** Antiepileptic Drug Substitution

**Date:** June 7, 2010

**Analyst:** Randall Chun

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: [www.house.mn/hrd](http://www.house.mn/hrd).

---

## Section

- 1** **Generally; rules.** Amends § 151.06, subd. 1. If the U.S. Food and Drug Administration (FDA) determines that the substitution of drugs used for the treatment of epilepsy or seizures poses a health risk to patients, requires the Board of Pharmacy to adopt rules on the use of substitution for these drugs in accordance with accompanying FDA interchangeability standards. Provides that if a rule regarding substitution conflicts with § 151.21, subd. 3 (current law substitution and dispense as written provision), then the rule supersedes the statute. If a rule proposed by the board would increase state costs for public health care programs, requires the board to report the proposed rule and associated cost increase to specified legislative committee chairs and ranking minority members before adopting the rule.